Open AccessTreatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
Author(s) -
Nørgaard Caroline Holm,
Friedrich Sarah,
Hansen Charlotte Thim,
Gerds Thomas,
Ballard Clive,
Møller Daniel Vega,
Knudsen Lotte Bjerre,
Kvist Kajsa,
Zinman Bernard,
Holm Ellen,
TorpPedersen Christian,
Mørch Lina Steinrud
Publication year - 2022
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1002/trc2.12268
Subject(s) - medicine , dementia , hazard ratio , type 2 diabetes , cohort , incidence (geometry) , randomized controlled trial , placebo , diabetes mellitus , clinical trial , disease , confidence interval , endocrinology , pathology , physics , alternative medicine , optics
People with type 2 diabetes have increased risk of dementia. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes. Methods We assessed exposure to GLP‐1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long‐term follow‐up: pooled data from three randomized double‐blind placebo‐controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry‐based cohort (120,054 patients). Results Dementia rate was lower both in patients randomized to GLP‐1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25–0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86–0.93 with yearly increased exposure to GLP‐1 RAs). Discussion Treatment with GLP‐1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.